Momenta Pharmaceuticals, Inc. Sustainability Profile
Momenta Pharmaceuticals, Inc., a leading biotechnology company headquartered in the United States, focuses on developing novel therapies for autoimmune diseases and rare disorders. Founded in 2001, Momenta has made significant strides in the industry, particularly with its innovative approach to monoclonal antibodies and complex generics. The company is renowned for its core product, M923, a biosimilar to a well-established therapeutic antibody, which exemplifies its commitment to providing high-quality, affordable treatment options. Momenta's unique expertise in molecular characterisation and analytical development sets it apart in the competitive biopharmaceutical landscape. With a strong market position, Momenta has achieved notable milestones, including successful collaborations and advancements in its pipeline, reinforcing its reputation as a pioneer in the biotechnology sector.
DitchCarbon Score
How does Momenta Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Momenta Pharmaceuticals, Inc.'s score of 78 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Momenta Pharmaceuticals, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Johnson & Johnson, and as such, it inherits emissions data and climate commitments from its parent organisation. While no direct emissions figures are provided, Momenta Pharmaceuticals aligns with the sustainability initiatives of Johnson & Johnson, which has set ambitious climate targets. These include commitments to reduce greenhouse gas emissions across its operations, with a focus on Scope 1, 2, and 3 emissions. The initiatives are part of a broader strategy to achieve net-zero emissions by 2030 for its operational footprint and to engage suppliers in reducing their emissions. Momenta Pharmaceuticals is also involved in various sustainability initiatives cascaded from Johnson & Johnson, including participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). These initiatives aim to enhance transparency and accountability in climate action. In summary, while specific emissions data for Momenta Pharmaceuticals is not available, the company is committed to sustainability through its association with Johnson & Johnson's comprehensive climate strategies and targets.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 1990 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 308,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 751,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 00,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Momenta Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is Momenta Pharmaceuticals, Inc.'s Location?
Momenta Pharmaceuticals, Inc.'s Scope 3 Categories Breakdown
Momenta Pharmaceuticals, Inc.'s Scope 3 emissions, which decreased by 2% last year and increased significantly since 2011, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 72% of Scope 3 emissions.
Top Scope 3 Categories
Momenta Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Momenta Pharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
